首页 > 市场调查报告书 > 製药

非专利药生技仿製药

市场调查报告书

商品编码

1922434

日本生物相似药市场报告：按分子、适应症、生产类型和地区划分（2026-2034年）

Japan Biosimilar Market Report by Molecule, Indication, Manufacturing Type, and Region 2026-2034

出版日期: 2026年01月01日 | 出版商:

IMARC | 英文 115 Pages | 商品交期: 5-7个工作天内

价格

简介目录

2025年，日本生物相似药市场规模达5.838亿美元。展望未来，IMARC集团预测，到2034年，该市场规模将达到36.196亿美元，2026年至2034年的复合年增长率将达到22.47%。推动市场成长的关键因素包括慢性病盛行率的上升、政府简化核准流程的措施、老龄化社会的需求、製药公司的积极参与、成本控制措施、公众意识的提高以及产品平臺的不断扩展。

生物相似药是一种与已已通过核准的参考生物药高度相似，且无临床意义差异的生物製品。与学名药品牌药的完全相同的复製品）不同，生物相似药是生物来源的复杂大分子，例如蛋白质或抗体。生物相似药的研发涉及对生物製剂与参考生物药的结构、功能和疗效进行全面比较。儘管生物製药固有的复杂性使得生产完全复製品是不可能的，但透过严格的测试和监管核准流程，生物相似药已被证明在安全性和疗效方面与参考生物药高度相似。生物相似药为昂贵的生物製药製剂提供了更经济实惠的替代方案，并在全球范围内日益受到重视，成为应对医疗成本不断上涨的一种手段，为医疗系统、医护人员和患者提供经济有效的治疗选择，同时又不影响疗效。

日本生物相似药市场趋势：

癌症和糖尿病等慢性疾病的日益增多，使得人们迫切需要经济有效的治疗方案，这是推动日本生物相似药市场成长的主要动力。因此，日本政府大力推广生物相似药的使用，并引入加快核准流程的法规结构，显着促进了市场成长。此外，人口老化也推动了对包括生物相似药在内的经济型医疗保健解决方案的需求，进一步刺激了市场成长。同时，许多老牌製药公司大力投资生物相似药的研发，也推动了市场成长。这些公司正利用自身的专业知识和资源，加速生物相似药的生产和商业化。此外，国内外製药公司之间广泛的合作与伙伴关係，促进了创新，并拓展了生物相似药的产品范围，进一步促进了市场成长。此外，受经济因素驱动，医疗保健行业致力于控制医疗成本，这为日本生物相似药市场提供了支持，使其成为在不影响疗效的前提下显着降低成本的有效途径。此外，医疗专业人员和患者对生物相似药的认知度和接受度不断提高，正在促进人们对这些替代疗法的积极看法，为市场扩张提供了广泛的机会。同时，对个人化医疗和标靶治疗的日益重视，以及涵盖多个治疗领域的生物相似药产品线的不断扩展，也为市场成长创造了积极的前景。

本报告解答的关键问题

日本生物相似药市场目前发展状况如何？您认为未来几年它将如何发展？
新冠疫情对日本生物相似药市场产生了哪些影响？
日本生物相似药市场按分子类型分類的市场组成为何？
日本生物相似药市场依适应症分類的情况如何？
日本生物相似药市场依生产方法分類的市场组成为何？
请介绍日本生物相似药市场价值链的各个环节。
日本生物相似药市场的主要驱动因素和挑战是什么？
日本生物相似药市场的结构是怎么样的？主要参与者有哪些？
日本生物相似药市场竞争有多激烈？

Japan biosimilar market size reached USD 583.8 Million in 2025 . Looking forward, IMARC Group expects the market to reach USD 3,619.6 Million by 2034 , exhibiting a growth rate (CAGR) of 22.47% during 2026-2034 . The increasing chronic disease prevalence, government initiatives for streamlined approvals, aging population demands, strong pharmaceutical company involvement, cost containment efforts, heightened awareness, and expanding product pipelines represent some of the key factors driving the market.

Access the full market insights report Request Sample

A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing, already approved reference biologic drug. Compared to generic versions of small-molecule drugs, which are identical replicas of their branded counterparts, biosimilars are large, complex molecules derived from living organisms, such as proteins or antibodies. The development of biosimilars involves a comprehensive comparison with the reference biologic, encompassing aspects like structure, function, and efficacy. Due to the inherent complexity of biologics, it is impossible to produce exact replicas; however, biosimilars are demonstrated to be highly similar in terms of safety and efficacy through rigorous testing and regulatory approval processes. Biosimilars offers a more affordable alternative to expensive biological drug and have gained prominence globally as a means to address the rising costs of healthcare, providing healthcare systems, practitioners, and patients with cost-effective options without compromising therapeutic benefits.

JAPAN BIOSIMILAR MARKET TRENDS:

The increasing prevalence of chronic diseases, such as cancer and diabetes, necessitating cost-effective treatment options is primarily driving the growth of the Japan biosimilar market. In line with this, the Japanese government's initiatives to promote the use of biosimilars, and the introduction of a regulatory framework to expedite the approval process, are significantly fueling the market growth. Moreover, the rising geriatric population in Japan underscores the demand for affordable healthcare solutions, such as biosimilars, strengthening the market growth. Besides this, the strong presence of established pharmaceutical companies investing in biosimilar research and development (R&D) is providing an impetus to the market growth as these companies leverage their expertise and resources to expedite the production and commercialization of biosimilar products. Concurrently, extensive collaborations and partnerships between domestic and international pharmaceutical firms stimulate innovation and widen the scope of biosimilar offerings, which is contributing to the market's growth. Along with this, the push for healthcare cost containment, driven by economic factors, further bolsters the biosimilar market in Japan, as these products provide an avenue for achieving significant cost savings without compromising on treatment efficacy. Additionally, the increasing awareness and acceptance of biosimilars among healthcare professionals and patients, fostering a positive perception of these alternatives, is presenting lucrative opportunities for the market expansion. Furthermore, the growing emphasis on personalized medicine and targeted therapies and the expanding pipeline of biosimilar products encompassing a diverse range of therapeutic areas are creating a positive outlook for the market growth.

JAPAN BIOSIMILAR MARKET SEGMENTATION:

Molecule Insights:

To get detailed segment analysis of this market Request Sample
Infliximab
Insulin Glargine
Epoetin Alfa
Etanercept
Filgrastim
Somatropin
Rituximab
Follitropin Alfa
Adalimumab
Pegfilgrastim
Trastuzumab
Bevacizumab
Others
Infliximab
Insulin Glargine
Epoetin Alfa
Etanercept
Filgrastim
Somatropin
Rituximab
Follitropin Alfa
Adalimumab
Pegfilgrastim
Trastuzumab
Bevacizumab
Others

Indication Insights:

Auto-Immune Diseases
Blood Disorder
Diabetes
Oncology
Growth Deficiency
Female Infertility
Others
Auto-Immune Diseases
Blood Disorder
Diabetes
Oncology
Growth Deficiency
Female Infertility
Others

Manufacturing Type Insights:

In-House Manufacturing
Contract Manufacturing
In-House Manufacturing
Contract Manufacturing

Regional Insights:

To get detailed regional analysis of this market Request Sample
Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

KEY QUESTIONS ANSWERED IN THIS REPORT
How has the Japan biosimilar market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan biosimilar market?
What is the breakup of the Japan biosimilar market on the basis of molecule?
What is the breakup of the Japan biosimilar market on the basis of indication?
What is the breakup of the Japan biosimilar market on the basis of manufacturing type?
What are the various stages in the value chain of the Japan biosimilar market?
What are the key driving factors and challenges in the Japan biosimilar?
What is the structure of the Japan biosimilar market and who are the key players?
What is the degree of competition in the Japan biosimilar market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Biosimilar Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Biosimilar Market Landscape

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 Japan Biosimilar Market - Breakup by Molecule

6.1 Infliximab
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2020-2025)
- 6.1.3 Market Forecast (2026-2034)
6.2 Insulin Glargine
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2020-2025)
- 6.2.3 Market Forecast (2026-2034)
6.3 Epoetin Alfa
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2020-2025)
- 6.3.3 Market Forecast (2026-2034)
6.4 Etanercept
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2020-2025)
- 6.4.3 Market Forecast (2026-2034)
6.5 Filgrastim
- 6.5.1 Overview
- 6.5.2 Historical and Current Market Trends (2020-2025)
- 6.5.3 Market Forecast (2026-2034)
6.6 Somatropin
- 6.6.1 Overview
- 6.6.2 Historical and Current Market Trends (2020-2025)
- 6.6.3 Market Forecast (2026-2034)
6.7 Rituximab
- 6.7.1 Overview
- 6.7.2 Historical and Current Market Trends (2020-2025)
- 6.7.3 Market Forecast (2026-2034)
6.8 Follitropin Alfa
- 6.8.1 Overview
- 6.8.2 Historical and Current Market Trends (2020-2025)
- 6.8.3 Market Forecast (2026-2034)
6.9 Adalimumab
- 6.9.1 Overview
- 6.9.2 Historical and Current Market Trends (2020-2025)
- 6.9.3 Market Forecast (2026-2034)
6.10 Pegfilgrastim
- 6.10.1 Overview
- 6.10.2 Historical and Current Market Trends (2020-2025)
- 6.10.3 Market Forecast (2026-2034)
6.11 Trastuzumab
- 6.11.1 Overview
- 6.11.2 Historical and Current Market Trends (2020-2025)
- 6.11.3 Market Forecast (2026-2034)
6.12 Bevacizumab
- 6.12.1 Overview
- 6.12.2 Historical and Current Market Trends (2020-2025)
- 6.12.3 Market Forecast (2026-2034)
6.13 Others
- 6.13.1 Historical and Current Market Trends (2020-2025)
- 6.13.2 Market Forecast (2026-2034)

7 Japan Biosimilar Market - Breakup by Indication

7.1 Auto-Immune Diseases
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2020-2025)
- 7.1.3 Market Forecast (2026-2034)
7.2 Blood Disorder
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2020-2025)
- 7.2.3 Market Forecast (2026-2034)
7.3 Diabetes
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2020-2025)
- 7.3.3 Market Forecast (2026-2034)
7.4 Oncology
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2020-2025)
- 7.4.3 Market Forecast (2026-2034)
7.5 Growth Deficiency
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2020-2025)
- 7.5.3 Market Forecast (2026-2034)
7.6 Female Infertility
- 7.6.1 Overview
- 7.6.2 Historical and Current Market Trends (2020-2025)
- 7.6.3 Market Forecast (2026-2034)
7.7 Others
- 7.7.1 Historical and Current Market Trends (2020-2025)
- 7.7.2 Market Forecast (2026-2034)

8 Japan Biosimilar Market - Breakup by Manufacturing Type

8.1 In-House Manufacturing
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2020-2025)
- 8.1.3 Market Forecast (2026-2034)
8.2 Contract Manufacturing
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2020-2025)
- 8.2.3 Market Forecast (2026-2034)

9 Japan Biosimilar Market - Breakup by Region

9.1 Kanto Region
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2020-2025)
- 9.1.3 Market Breakup by Molecule
- 9.1.4 Market Breakup by Indication
- 9.1.5 Market Breakup by Manufacturing Type
- 9.1.6 Key Players
- 9.1.7 Market Forecast (2026-2034)
9.2 Kansai/Kinki Region
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2020-2025)
- 9.2.3 Market Breakup by Molecule
- 9.2.4 Market Breakup by Indication
- 9.2.5 Market Breakup by Manufacturing Type
- 9.2.6 Key Players
- 9.2.7 Market Forecast (2026-2034)
9.3 Central/ Chubu Region
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2020-2025)
- 9.3.3 Market Breakup by Molecule
- 9.3.4 Market Breakup by Indication
- 9.3.5 Market Breakup by Manufacturing Type
- 9.3.6 Key Players
- 9.3.7 Market Forecast (2026-2034)
9.4 Kyushu-Okinawa Region
- 9.4.1 Overview
- 9.4.2 Historical and Current Market Trends (2020-2025)
- 9.4.3 Market Breakup by Molecule
- 9.4.4 Market Breakup by Indication
- 9.4.5 Market Breakup by Manufacturing Type
- 9.4.6 Key Players
- 9.4.7 Market Forecast (2026-2034)
9.5 Tohoku Region
- 9.5.1 Overview
- 9.5.2 Historical and Current Market Trends (2020-2025)
- 9.5.3 Market Breakup by Molecule
- 9.5.4 Market Breakup by Indication
- 9.5.5 Market Breakup by Manufacturing Type
- 9.5.6 Key Players
- 9.5.7 Market Forecast (2026-2034)
9.6 Chugoku Region
- 9.6.1 Overview
- 9.6.2 Historical and Current Market Trends (2020-2025)
- 9.6.3 Market Breakup by Molecule
- 9.6.4 Market Breakup by Indication
- 9.6.5 Market Breakup by Manufacturing Type
- 9.6.6 Key Players
- 9.6.7 Market Forecast (2026-2034)
9.7 Hokkaido Region
- 9.7.1 Overview
- 9.7.2 Historical and Current Market Trends (2020-2025)
- 9.7.3 Market Breakup by Molecule
- 9.7.4 Market Breakup by Indication
- 9.7.5 Market Breakup by Manufacturing Type
- 9.7.6 Key Players
- 9.7.7 Market Forecast (2026-2034)
9.8 Shikoku Region
- 9.8.1 Overview
- 9.8.2 Historical and Current Market Trends (2020-2025)
- 9.8.3 Market Breakup by Molecule
- 9.8.4 Market Breakup by Indication
- 9.8.5 Market Breakup by Manufacturing Type
- 9.8.6 Key Players
- 9.8.7 Market Forecast (2026-2034)

10 Japan Biosimilar Market - Competitive Landscape

10.1 Overview
10.2 Market Structure
10.3 Market Player Positioning
10.4 Top Winning Strategies
10.5 Competitive Dashboard
10.6 Company Evaluation Quadrant

11 Profiles of Key Players

11.1 Company A
- 11.1.1 Business Overview
- 11.1.2 Product Portfolio
- 11.1.3 Business Strategies
- 11.1.4 SWOT Analysis
- 11.1.5 Major News and Events
11.2 Company B
- 11.2.1 Business Overview
- 11.2.2 Product Portfolio
- 11.2.3 Business Strategies
- 11.2.4 SWOT Analysis
- 11.2.5 Major News and Events
11.3 Company C
- 11.3.1 Business Overview
- 11.3.2 Product Portfolio
- 11.3.3 Business Strategies
- 11.3.4 SWOT Analysis
- 11.3.5 Major News and Events
11.4 Company D
- 11.4.1 Business Overview
- 11.4.2 Product Portfolio
- 11.4.3 Business Strategies
- 11.4.4 SWOT Analysis
- 11.4.5 Major News and Events
11.5 Company E
- 11.5.1 Business Overview
- 11.5.2 Product Portfolio
- 11.5.3 Business Strategies
- 11.5.4 SWOT Analysis
- 11.5.5 Major News and Events

12 Japan Biosimilar Market - Industry Analysis

12.1 Drivers, Restraints, and Opportunities
- 12.1.1 Overview
- 12.1.2 Drivers
- 12.1.3 Restraints
- 12.1.4 Opportunities
12.2 Porters Five Forces Analysis
- 12.2.1 Overview
- 12.2.2 Bargaining Power of Buyers
- 12.2.3 Bargaining Power of Suppliers
- 12.2.4 Degree of Competition
- 12.2.5 Threat of New Entrants
- 12.2.6 Threat of Substitutes
12.3 Value Chain Analysis

13 Appendix

02-2729-4219

+886-2-2729-4219

License/价格

日本生物相似药市场报告：按分子、适应症、生产类型和地区划分（2026-2034年）